Statistics for TScan Therapeutics, (id:6915 TCRX)

Valuation metrics

Market cap

227.36M

Enterprise value

29.52M

Trailing P/E (ttm)

-3.12

Forward P/E

-3.30

PEG ratio

-3.30

Price/Sales (ttm)

24.29

Price/Book (mrq)

0.99

Enterprise Value/Revenue

3.15

Enterprise Value/EBITDA

-0.26

Overview

Shares outstanding

49.09M

Float

31.13M

Shares short

2.16M

% Held by insiders

0.01%

% Held by institutions

0.99%

Average volume (10 days)

205.39K

Average volume (90 days)

Price summary

52-Week low

3.92

52-Week high

9.69

52-Week change

-21.60%

Beta

0.78

50-Day moving average

5.18

200-Day moving average

6.59

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-3,109.82%

Operational effectiveness

Return on assets

-23.36%

Return on equity

-55.92%

Income statement

Revenue (ttm)

0.18

Revenue per share (ttm)

0.18

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-114,789,000.00

Net income to common (ttm)

-111,303,000.00

Diluted EPS (ttm)

-0.95

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

271.12M

Total cash per share (mrq)

5.08

Total debt (mrq)

90.36M

Total Debt/Equity (mrq)

39.44

Current ratio (mrq)

956.30%

Book value per share (mrq)

4.29

Cash flow

Cash flow statement

-107,176,000.00

Levered free cash flow (LFCF)

-71,110,872.00